



**FROM THE EDITOR**

Dear colleagues,

I am extremely pleased to be writing my first editorial preface. I would like to express my sincere greetings to all readers of Asthma Allergy Immunology as the new editor. I have taken over during the XXVIIIth National Congress of Allergy and Clinical Immunology in October 2011 with great honor. I will be working with a strong team of associate editors including Pınar Uysal, Şadan Soyyiğit, Feridun Gürlek, Ayça Kıyım, Özlem Cavkaytar, Murat Türk, Esra Özek Yücel, Ayşe Bilge Öztürk, Ayşe Baççioğlu and Semanur Kuyucu. It will be our privilege to serve the journal in the next 3-year period. We wish to express our gratitude and appreciation to the previous editor Prof. Gül Karakaya and associated editors for their outstanding contributions to the growing reputation of the journal. We also would like to thank all previous editors and associate editors who served to improve our journal until now. Our journal is currently indexed in the Turkish Medical Index of TUBITAK/ULAKBİM, EBSCOhost Research Databases, Index Copernicus, CINAHL, Turkey Citation Index, Web of Science and Emerging Sources Citation Index. We are excited about the future of the journal and are committed to helping continue the impressive progress it has established over the past years.

We are happy to present you the first issue of 2022 of Asthma Allergy Immunology as the new editorial team. We published eight very valuable research articles, one case report and one letter to the editor in this issue. The first research article is on the relation between vit-D levels and patients with rhinitis as allergic and non-allergic. The second research article contains detailed data about the characteristics of adverse reactions and compliance in patients who underwent allergen-specific subcutaneous immunotherapy. The third research article on the effect of an elimination diet on early childhood growth in children with egg and/or cow's milk allergies. In the fourth research article, the authors assess the effectiveness of omalizumab on patients who met the criteria of asthma-chronic obstructive pulmonary disease overlap. The fifth research article is about hyperamylasemia during omalizumab therapy. In the sixth research article, the authors evaluate the clinical outcome of all the patients undergoing omalizumab treatment, including its safety profile and effectiveness in various indications at their tertiary clinic. In the seventh study, the aim was to evaluate the patients who had completed allergen immunotherapy in terms of clinical improvement and new allergic sensitizations in the skin prick test. The last research article is about the awareness concerning primary immunodeficiencies among physicians in Turkey. The case report of this issue is a patient who presented to the pediatric allergy and clinical immunology outpatient clinic with signs of ichthyosis, multiple food allergy, anaphylaxis, hypereosinophilia, and hyperimmunoglobulinemia E. In the letter to the editor, the authors report a successful idursulfase desensitization experience in a pediatric patient.

We would like to thank you for your unwithholding support to our journal by submitting your valuable papers and citing our journal in your articles published in other journals. We continue to go on our way with your support.

Sincerely,

**İnsu Yılmaz, MD, Professor**  
Editor in Chief